---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-056077"
form_type: "8-K"
ticker: "BLLN"
cik: "0002070849"
company_name: "BillionToOne, Inc."
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:51:51.617418+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BillionToOne Q3 revenue $83.5M (+117% YoY); guides FY2025 revenue $293-299M

## Summary
- Q3 total revenue $83.5M (+117% YoY); prenatal revenue $74.1M (+102%), oncology $8.7M (7.6x YoY).
- GAAP operating income of $9.6M vs. ($12.6M) loss YoY; net income $1.5M ($0.10 diluted EPS).
- Gross margin improved to 70% from 53% YoY; tests delivered up 52% to 165,000; ASP up 44% to $501.
- Guides FY2025 revenue $293-299M (93-96% growth); expects positive operating income for Q4 and full year.
- Appointed Anthony Pagano (Genmab CFO) as Audit Committee Chair, effective Jan 1, 2026.

## SEC filing metadata
- accession: 0001628280-25-056077
- form_type: 8-K
- ticker: BLLN
- cik: 0002070849
- company_name: BillionToOne, Inc.
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2070849/000162828025056077/0001628280-25-056077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2070849/000162828025056077/blln-20251209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-056077
- JSON: https://secwatch.observer/filing/0001628280-25-056077.json
- Plain text: https://secwatch.observer/filing/0001628280-25-056077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.